Revenue Breakdown
Composition ()
No data
Revenue Streams
Amphastar Pharmaceuticals Inc (AMPH) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Other finished pharmaceutical products, accounting for 19.0% of total sales, equivalent to $34.65M. Other significant revenue streams include Epinephrine and Glucagon. Understanding this composition is critical for investors evaluating how AMPH navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Amphastar Pharmaceuticals Inc maintains a gross margin of 46.79%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 19.45%, while the net margin is 13.34%. These profitability ratios, combined with a Return on Equity (ROE) of 12.90%, provide a clear picture of how effectively AMPH converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, AMPH competes directly with industry leaders such as SPRY and BCAX. With a market capitalization of $917.84M, it holds a significant position in the sector. When comparing efficiency, AMPH's gross margin of 46.79% stands against SPRY's 74.80% and BCAX's N/A. Such benchmarking helps identify whether Amphastar Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.
